CDKN2B-AS1 and neoplasm: One meta-analysis published in 2022, based on a sample of 1708 cancer patients extracted from 23 studies across three databases, could also established a clear correlation between high ANRIL expression, adverse overall survival rates, larger tumor size, advanced TNM stage, and lymph node metastasis [84].